Thomas John Dietz is Director at Eiger BioPharmaceuticals, Inc. (EIGR). They have made 11 open-market trades across 3 companies since 2018, most recently 2026-08-26.
CIK 0001574218
8 open-market purchases totalling $370K since 2018, against 3 sales. Across 8 scored buys the stock is up 8.5% at ninety days, and 3.1 points ahead of the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| CYPH | 132,500 | $341K |
| EIGR | 50,000 | $86K |
| PRTK | 20,000 | $45K |
| TSPT | 5,430 | — |
| Total | $471K |
Shares reported on the most recent Form 4, priced at the 2026-08-27 close. 1 holding could not be priced and is excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 75% | 50% |
| Avg Move | +8.2% | +13.4% | +8.5% |
| Alpha | +8.0% | +11.4% | +3.1% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CYPH | SELL | 2026-08-26 | 2026-08-27 | $1.72 | $34K | +34.3% | +81.9% | — |
| EIGR | BUY | 2023-01-23 | 2023-01-25 | $1.43 | $72K | +55.9% | +25.5% | -31.0% |
| EIGR | SELL | 2022-12-22 | 2022-12-27 | $1.17 | $26K | +10.3% | +30.8% | -5.6% |
| EIGR | BUY | 2021-04-09 | 2021-04-12 | $8.49 | $21K | +2.2% | -2.6% | +2.5% |
| EIGR | BUY | 2020-03-16 | 2020-03-17 | $4.95 | $5K | +27.4% | +42.7% | +96.0% |
| EIGR | BUY | 2020-01-10 | 2020-01-13 | $13.94 | $56K | -3.8% | -13.5% | -42.3% |
| EIGR | BUY | 2019-04-23 | 2019-04-23 | $11.10 | $56K | -4.4% | +2.9% | -2.2% |
| EIGR | BUY | 2019-04-22 | 2019-04-22 | $11.05 | $55K | -4.8% | +2.2% | -4.6% |
| PRTK | SELL · 10b5-1 | 2019-02-15 | 2019-02-20 | $7.14 | $21K | -4.5% | -18.8% | -38.3% |
| PRTK | SELL | 2018-12-21 | 2018-12-26 | $5.01 | $47K | +27.7% | +45.5% | +16.9% |
| EIGR | BUY | 2018-12-20 | 2018-12-20 | $9.98 | $50K | +4.6% | +35.1% | +33.1% |
| EIGR | BUY | 2018-12-06 | 2018-12-10 | $11.26 | $56K | -11.4% | +14.7% | +16.8% |
| PRTK | SELL · 10b5-1 | 2018-02-05 | 2018-02-07 | $14.22 | $30K | -1.1% | +4.7% | -19.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.